Luminex (NASDAQ:LMNX) Reaches New 52-Week Low at $19.95

Luminex Co. (NASDAQ:LMNX) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as $19.95 and last traded at $19.95, with a volume of 2268 shares changing hands. The stock had previously closed at $20.21.

Several analysts have recently commented on LMNX shares. Zacks Investment Research raised shares of DLH from a “sell” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 17th. BidaskClub cut shares of Amyris from a “hold” rating to a “sell” rating in a research note on Thursday, June 27th. Finally, William Blair reaffirmed a “market perform” rating on shares of Luminex in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the stock. Luminex presently has a consensus rating of “Hold” and a consensus target price of $25.67.

The firm has a market capitalization of $925.63 million, a PE ratio of 41.44, a P/E/G ratio of 19.06 and a beta of 0.75. The company has a quick ratio of 2.70, a current ratio of 3.99 and a debt-to-equity ratio of 0.04. The stock’s 50 day moving average is $20.92.

Luminex (NASDAQ:LMNX) last announced its quarterly earnings data on Monday, May 6th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.14). Luminex had a net margin of 2.55% and a return on equity of 1.62%. The business had revenue of $82.41 million during the quarter, compared to the consensus estimate of $83.10 million. During the same period in the previous year, the business posted $0.30 earnings per share. Luminex’s revenue was down .3% compared to the same quarter last year. As a group, equities analysts forecast that Luminex Co. will post 0.07 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Thursday, June 20th will be issued a $0.06 dividend. The ex-dividend date is Wednesday, June 19th. This represents a $0.24 annualized dividend and a yield of 1.21%. Luminex’s dividend payout ratio (DPR) is presently 50.00%.

Institutional investors and hedge funds have recently bought and sold shares of the business. Texas Permanent School Fund raised its holdings in Luminex by 3.9% in the fourth quarter. Texas Permanent School Fund now owns 27,131 shares of the medical instruments supplier’s stock worth $627,000 after purchasing an additional 1,028 shares during the period. Geode Capital Management LLC raised its holdings in Luminex by 10.3% in the fourth quarter. Geode Capital Management LLC now owns 526,958 shares of the medical instruments supplier’s stock worth $12,177,000 after purchasing an additional 49,411 shares during the period. Rhumbline Advisers raised its holdings in Luminex by 0.6% in the first quarter. Rhumbline Advisers now owns 128,066 shares of the medical instruments supplier’s stock worth $2,947,000 after purchasing an additional 822 shares during the period. Norges Bank acquired a new stake in Luminex in the fourth quarter worth $22,764,000. Finally, Bank of Montreal Can raised its holdings in Luminex by 985.0% in the first quarter. Bank of Montreal Can now owns 84,513 shares of the medical instruments supplier’s stock worth $1,944,000 after purchasing an additional 76,724 shares during the period. Institutional investors own 84.66% of the company’s stock.

About Luminex (NASDAQ:LMNX)

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.

Recommended Story: Closed-End Mutual Funds

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.